GENECAPTURE, INC. — Department of Defense STTR Phase II: CBD15C-001
GENECAPTURE, INC. — STTR Phase II award from Department of Defense.
- Amount
- $994,238
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- STTR · Phase II
- Topic
- CBD15C-001
- Solicitation
- 2015.0
- NAICS
- —
- Place of performance
- AL
- Period
- 2018-03-16 → 2020-03-15
Description
GeneCapture, Inc. is proposing to develop a rapid in vitro diagnostic prototype using our patented molecular-based CAPTURE (ConfirmActive Pathogens Through Unamplified RNA Expression) assay. Based on the results and experience gained in our Phase I STTR contractHDTRA1-16C-0061: Infectious Disease Diagnostics and Differentiation of Viral vs. Bacterial Infections for Point of Care Applications, we plan tocontinue our device maturation by integrating automated sample preparation into the disposable cartridge, modifying the fluid path foroptimal target acquisition, expanding the Febrile Illness panel and progressing the commercialization of the product. The goal of this Topic is aportable pathogen detection system for undifferentiated febrile illnesses for use in far-forward environments by the Warfighter. Thepathogens of interest for this Phase II effort include Influenza, Dengue, Chikungunya, Lassa Fever, and Crimean-Congo Hemorrhagic Feverviruses, and the bacteria Yersinia pestis, Rickettsia typhi, Francisella tularensis and Burkholderia species. The assay will also differentiatesamples containing bacterial agents from those containing fungal or viral pathogens.